

JUBILANT PHARMA LIMITED
(Company Registration No. 200506887H)
(Incorporated in the Republic of Singapore)
Registered office: 80 Robinson Road, #02-00, Singapore 068898

March 21, 2019

Singapore Exchange Securities Trading Limited

11 North Buona Vista Drive #06-07
The Metropolis Tower 2
Singapore 138589

Dear Sirs,

We enclose a communication pertaining to USFDA inspection update.

This is for your kind information and records.

Thanking you,

Yours faithfully,
For Jubilant Pharma Limited



Arun Kumar Sharma
Chief Financial Officer

Encl.: as above



Jubilant Pharma Ltd.

6 Temasek Boulevard, #20-06

Suntec City Tower Four, Singapore 038986

Tel.: +65 6235 4129

www.jubilantpharma.com

USFDA Inspection Update - API Facility at Nanjangud

Noida (UP), India, Friday, March 21, 2019

Jubilant Pharma Limited, a material wholly owned subsidiary of Jubilant Life Sciences Ltd, has been informed by the U.S. Food and Drug Administration (USFDA), in correspondence dated March 13, 2019, received on March 21, 2019, that the inspection from December 10-18, 2018 at the Jubilant Generics Limited (JGL) (FEI: 3003144728) API manufacturing facility, in Nanjangud, Mysore, has been classified as "Official Action Indicated" (OAI). The USFDA also stated that the facility might be subject to a cGMP regulatory or enforcement action based on this inspection, and that FDA could withhold approval of any pending applications or supplements in which this facility is listed.

FDA's announcement will not have any impact on the existing revenues from operations of this facility. We believe that this letter has been issued as part of a USFDA initiative to respond to the company within 90 days of the inspection, regarding the facility's status. As per the agency's internal procedures, the company can engage with the agency within 40 days to seek to get the decision downgraded from the OAI classification. In that regard, Jubilant is in the process of sending a further update to USFDA of its corrective actions regarding the agency's inspectional observations from December 2018.

About Jubilant Pharma Limited

Jubilant Pharma Limited (JPL), a company incorporated under the laws of Singapore and a wholly owned subsidiary of Jubilant Life Sciences Limited, is an integrated global Pharmaceutical company engaged in manufacturing and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectables and Non-sterile products through 5 USFDA approved manufacturing facilities in the US, Canada and India and a network of over 50 radio-pharmacies in the US. The Company has a team of over 4,300 multicultural people across the globe and is committed to deliver value to its customers spread across over 75 countries. It is well recognized as a 'Partner of Choice' by leading pharmaceutical companies globally.

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors. For detailed disclaimer in case of Jubilant Pharma Limited, please visit <http://www.jubilantpharma.com/fullpage.aspx?mpgid=1147&pgid=1147>